Zentalis Pharmaceuticals Files 8-K

Ticker: ZNTL · Form: 8-K · Filed: Mar 17, 2025 · CIK: 1725160

Sentiment: neutral

Topics: sec-filing, 8-k

TL;DR

Zentalis filed an 8-K on 3/15/25, check for updates.

AI Summary

On March 15, 2025, Zentalis Pharmaceuticals, Inc. filed an 8-K report. The filing primarily concerns Regulation FD Disclosure and Financial Statements and Exhibits. No specific material events or financial figures were detailed in the provided excerpt.

Why It Matters

This filing indicates Zentalis Pharmaceuticals is providing updates or disclosures to the SEC, which could contain important information for investors.

Risk Assessment

Risk Level: low — The provided text is a standard SEC filing notification and does not contain specific material events or financial data that would indicate a change in risk.

Key Players & Entities

FAQ

What is the primary purpose of this 8-K filing by Zentalis Pharmaceuticals?

The filing is a Current Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, primarily for Regulation FD Disclosure and Financial Statements and Exhibits.

On what date was this 8-K report filed?

The filing was made on March 17, 2025, and the earliest event reported is dated March 15, 2025.

What is Zentalis Pharmaceuticals' Standard Industrial Classification code?

Zentalis Pharmaceuticals' SIC code is 2834, which corresponds to Pharmaceutical Preparations.

What is the business address of Zentalis Pharmaceuticals?

The business address is 10275 Science Center Drive, Suite 200, San Diego, CA 92121.

Has Zentalis Pharmaceuticals operated under any previous names?

Yes, Zentalis Pharmaceuticals, Inc. was formerly known as Zentalis Pharmaceuticals, LLC (name change effective January 7, 2020) and prior to that, Zeno Pharma, LLC (name change effective December 12, 2017).

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on March 17, 2025 regarding Zentalis Pharmaceuticals, Inc. (ZNTL).

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing